Renal Cell Cancer


Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine.

Renal cell carcinoma is a form of kidney cancer.

Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney.


Cabozantinib (Cabometyx) is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys) that has worsened after treatment with other chemotherapy medications.

Everolimus is approved to treat: Renal cell carcinoma (a type of kidney cancer) that is advanced, in adults who have not gotten better with other chemotherapy.

Aldesleukin is approved to treat: Renal cell carcinoma (a type of kidney cancer) that has metastasized.

Sutent - Sunitinib Malate (G) is used to treat certain types of cancer (kidney, pancreas, and intestinal). Sunitinib works by stopping or slowing the growth of cancer tumors.

Pazopanib is used to treat kidney cancer. It may also be used to treat certain other types of cancer (soft tissue sarcoma). Pazopanib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by decreasing the blood supply to the cancer tumor to slow tumor growth.



Relevant Articles

J Wagstaff, R Jones, R Hawkins, E Porfiri, L Pickering, A Bahl, J Brown, S Buchan
Annals of Oncology 2016-01-01
The aim of the RECCORD registry was to gather real-world UK data on the use of targeted therapies in renal cell carcinoma (RCC) and assess clinical outcomes. Here, demographic and outcome data are presented with the treatment patterns and demographic profile of patients on the registry. Patients were retrospectively identified a...Read More
Nobuo Shinohara, Takashige Abe
International Journal of Urology 2015-10-01
The introduction of molecular-targeted therapy has made dramatical changes to treatment for metastatic renal cell carcinoma. Currently, there are four vascular endothelial growth factor receptor-tyrosine kinase inhibitors and two mammalian target of rapamycin inhibitors in Japan. For the appropriate clinical use of these molecul...Read More
Su-Jin Shin, Yoon Kyung Jeon, Yong Mee Cho, Jae-Lyun Lee, Doo Hyun Chung, Ji Young Park, Heounjeong Go
Oncologist 2015-11-01
Vascular endothelial growth factor pathway (VEGF)-tyrosine kinase inhibitors (TKIs) are used as the first-line treatment for patients with metastatic clear cell renal cell carcinoma (mCCRCC). Recently, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) blockade emerged as promising therapy for renal cell carcinoma. ...Read More
Related Links